About this trial
1.to evaluate the potential role of the optic nerve diameter ( OND determined by ultrasonography and and visual nerve function by visual evoked potential as a biomarker of early axonal loss and disability in patients with relapsing remitting multiple sclerosis (RRMS).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
1. both sex
Age group from 15 to 50 yrs
Patient with RRMS without history of optic neuritis
Disqualifiers
History of previous optic neuritis
Medical illness of eye(e.g. diabetes and hypertension)
MS patient on fingolimod for 6 months or more
Relapsing or use of steroid in the past 3 months
Trial population
both sex and RRMS with out previous optic neuritis
Trial design
Case-control
Prospective
Treatments tested in this trial
sonography
Devicemeasurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
Treatment groups
Trial outcomes
Primary outcomes
optic nerve measurement and correlation with axonal affection in RRMS
measurement of optic nerve diameter and optic nerve sheath diameter (in millimeter) in predicting progression in RRMS (Relapsing remitting multiple sclerosis)
Secondary outcomes
2.Correlation of ultrasonography and visual evoked potential (change in p100 latency) with physical disability and cognitive score and fatigue by Multiple Sclerosis Functional Composite
Correlation of ultrasonography and visual evoked potential (change in p100 latency) with physical disability and cognitive score and fatigue by Multiple Sclerosis Functional Composite The score is based on a combination of timed tests of walking, arm function, and cognitive ability An integrated Multiple Sclerosis Functional Composite (MSFC) score is calculated using z-scores
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: